Chemotherapy in the elderly with breast cancer

FORUM - Trends in Experimental and Clinical Medicine

Volumn 12, Issue 1, 2002, Pages 64-70

  Repetto, Lazzaro ^a   Pietropalo, Maria ^b   Aapro, Matti ^c  

^a INRCA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Inst Multidisciplinaire d'Oncologie   (Switzerland)

Author keywords

Breast cancer; Chemotherapy; Elderly

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPOSOME; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; TAXANE DERIVATIVE;

ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALOPECIA; AXILLARY LYMPH NODE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GERIATRIC CARE; HEMATOLOGIC DISEASE; HUMAN; LYMPH NODE DISSECTION; NEUROTOXICITY; PRACTICE GUIDELINE; PROTEIN EXPRESSION; REVIEW; TUMOR DIFFERENTIATION;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMOGRAPHY; PATIENT SELECTION;

EID: 0037001199     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Alberg AJ and Singh S. Epidemiology of breast cancer in older women: implications for future healthcare. Drugs Aging 2001; 18: 761-772.
2. Klimmick GG and Balducci L. Breast cancer and aging: clinical interactions. Hematol. Oncol. Clin. North Am. 2000; 14: 213-234.
3. Surveillance, Epidemiology and End Results (SEER) Program: Public use CD-ROM (1973-1995). Bethesda (MD): Cancer Statistic Branch, National Cancer Institute, 1998.
4. Parkin DM et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 2001; 37: S4-66.
5. Levi F et al. Changed trends of cancer mortality in the elderly. Ann. Oncol. 2001; 12: 1467-1477.
6. Coleman EA and O'Sullivan P. Racial differences in breast cancer screening among women from 65 to 74 years of age: trends from 1987-1993 and barriers to screening. J. Women Aging 2001; 13: 23-39.
7. Veronesi U et al. Breast conservation is the treatment of choice in small breast cancer: long term result of a randomized trial. Eur. J. Cancer 1990, 26: 668-670.
8. Holmes FF. Clinical course of cancer in the elderly. Cancer Control 1994; 1: 108-114.
9. Diab SG et al. Tumour characteristics and clinical outcome of elderly women with breast cancer. J. Natl. Cancer Inst. 2000; 92: b550-555.
10. Gajdos C et al. The consequence of undertreating breast cancer in the elderly. J. Am. Coll. Surg. 2001; 192: 698-707.
11. Van Hoeyweghen RJ Z. Gerontol. Geriatr. 2001; 34: 192-195.
12. Johs-Artisensi J and McGill J. Screening mammography for elderly women. Cancer Pract. 2001; 9: 128-133.
13. Hooper SB et al. Tamoxifen as the primary treatment in elderly patients with breast cancer. Ir. J. Med. Sci. 2002, 171: 28-30.
14. NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA 1985; 254: 3461-3462. NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA 1991; 265: 391-395.
15. The Steering committee on clinical practice guidelines for the care and treatment of breast cancer. Adjuvant systemic therapy for women with node-negative breast cancer. Can. Med. Assoc. J. 1998; 158 (Suppl 3): S43-51.
16. The Steering committee on clinical practice guidelines for the care and treatment of breast cancer. Adjuvant systemic therapy for women with node-positive breast cancer. Can. Med. Assoc. J. 1998; 158 (Suppl 3): S52-64.
17. National Institutes of Health. Adjuvant therapy for breast cancer. NIH consensus statement ondine 2000; 17: 1-23.
18. Muss HB. The role of chemotherapy and adjuvant therapy in the management of breast cancer in older women. Cancer 1994; 74: 2165-2171.
19. Hortobagyi GN. Treatment of breast cancer. N. Engl. J. Med. 1998; 339: 974-984.
20. Early Breast cancer trialists' collaborative group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N. Engl. J. Med. 1988; 319: 1681-1692.
21. Early Breast cancer trialists' collaborative group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immuno therapy. 133 randomised trias involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15, 71-85.
22. Early Breast cancer trialists' collaborative group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930-942.
23. Khayat D et al. Taxol in the management of cancers of the breast and the ovary. Cancer Invest. 2000; 18: 242-260.
24. Fisher B. Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. CA Cancer J. Clin. 1999; 49: 159-177.
25. Sledge GW Jr et al. Phase II trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: an intergroup trial. Proc. Am. Soc. Clin. Oncol. 1997; 16: 1.
26. Paridaens R et al. Paclitaxel versus doxorubucin as first line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of cancer randomized study with cross-over. J. Clin. Oncol. 2000; 18: 724-733.
27. Seidman AD et al. Phase II trial of paclitaxel by 3-hours infusion as initial and salvage chemotherapy for metastatic breast cancer. J. Clin. Oncol. 1995; 13: 2575-2581.
28. Seidman AD et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 1998; 16: 3353-3361.
29. Waintraub SE et al. Phase II study to evacuate the efficacy of weekly paclitaxel in patients with metastatic breast cancer who have failed prior anthracycline +/- taxane therapy. Proc. Am. Soc. Clin. Oncol. 2000; 19: 121 (abs. 470).
30. Perez EA et al. Multicenter phase II trial of Paclitaxel in women with metastatic breast cancer. JCO 2001; 19: 4216-4223.
31. Sledge GW Jr et al. Changes in quality of life (QOL) during induction therapy in patients enrolled in a randomized trial of adriamycin plus taxol in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 1997; 16: 54.
32. Hainsworth JD et al. Weekly Docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network Phase II Trial. J. Clin. Oncol. 2001; 19: 3500-3505.
33. Constenla M et al. Docetaxel (TXT) monotherapy & G-CSF for advanced breast cancer (ABC) in elderly patients (REP). Proc. Am. Soc. Clin. Oncol. 2000; 19: 110a.
34. Sorio R et al. Pharmacokinetics and tollerance of vinorelbine in eldelry patients with metastatic breast cancer. Eur. J. Cancer 1997; 33: 301-303.
35. Vogel C et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann. Oncol. 1999; 10: 397-402.
36. Rossi A et al. Single agent Vinorelbine in elderly patients with advanced breast cancer: a multicenter phase II study. Proc. Am. Soc. Clin. Oncol. 2001; 20: 61b.
37. Procopio G et al. A phase II study of Capecitabine in elderly patients with advanced breast cancer. ASCO on line 2001 (abs. 3134).
38. Luftner D et al. Gemcitabine for palliative treatment in metastatic breast cancer. J. Cancer Res. Clin. Oncol. 1998; 124: 527-531.
39. Ranson MR et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J. Clin. Oncol. 1997; 15: 3185-3191.